Analysis and data insight - Articles - Page 279

Biopharmaceutical collaborations: January 2020

Feb. 21, 2020

Biopharma licensings, joint ventures and collaborations, including: 4SC, Abbvie, Amgen, Aska, Astellas, Astrazeneca, Bayer, Biogen, Biomed X, Boehringer, Chiesi Farmaceutici, Clinigen, Curis, Cyclica, Daewoong, Daiichi Sankyo, Evotec, Gilead, Hikma, Innovent, Inovio, Ionis, Iovance, Janssen, Mediwound, Merck & Co., Merck KGaA, Mundipharma, Nestle, Novartis, Novo Nordisk, Pfizer, Pharmamar, Phasebio, Probiogen, Roche, Schrodinger, Syndivia, Takeda.

Biggest gainers and losers for the week of Feb. 17-21, 2020

Feb. 21, 2020

The top 10 biopharma stock gainers and losers for the week.

Med-tech gainers and losers for Feb. 18-21, 2020

Feb. 21, 2020

The top 10 med-tech stock gainers and losers for the week.

Cancer cell destruction by nanoparticles

Over the speed bump

Biopharmas developing cancer drugs whipsaw into 2020

Feb. 18, 2020

By Peter Winter

The BioWorld Cancer index, which includes 21 representative companies developing therapies targeting various cancers, entered the new year on a high note, after posting a 22.5% gain for the year. Unfortunately, the group hit a speed bump and the index took a beating in January, dropping almost 9% as a result.

Week in review for Feb. 10-14, 2020: Candidate therapies hit speed bumps

Feb. 18, 2020

By Peter Winter

A quick look back at top stories, including: Advaxis, Avrobio, Beam, Biohaven, Blue Water, CNS, Collegium, Cortexyme, Deciphera, Eli Lilly, Genprex, Gibson, I-Mab, Inato, Logicbio, Moderna, Personalis, Promedior, Revance, Revolution, Roche, Syros, Theravance, Xeris, WPD.

Money raised by biopharma: 2020 vs. 2019

Feb. 14, 2020

Total raised in public, private and other financings of biopharma companies, comparing 2020 vs. 2019.

Biopharma money raised: Jan. 1-Feb. 13, 2020

Feb. 14, 2020

Year-to-date money raised in public, private and other financings of biopharma companies.

Regulatory submissions, approvals and other actions: January 2020

Feb. 14, 2020

Regulatory decisions affecting biopharma products in development, including: Abbvie, Aimmune, Alkermes, Alnylam, Amarin, Biohaven, Biolinerx, Blueberry, Clovis, Cytodyn, Durect, Emergent, Evoke, Exelixis, Fate, F-star, Galapagos, Genmab, Horizon, Incyte, Ipsen, Janssen, Jubilant, Mesoblast, Nabriva, Nektar, Nicox, Orion, Pharmacyte, Pharming, Pulmatrix, Recordati, Regeneron, Seelos, Sorrento, Ultragenyx, Vistagen.